Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 FORM 10-Q Commission File Number: 001-13992 RCI HOSPITALITY HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38042 _____________________________________ Securities re ...

TABLE OF CONTENTS SIMON PROPERTY GROUP EARNINGS RELEASE & SUPPLEMENTAL INFORMATION UNAUDITED FIRST QUARTER TABLE OF CONTENTS TABLE OF CONTENTS | EARNINGS RELEASE AND SUPPLEMENTAL INFORMATION | | | --- | --- | | FOR THE QUARTER ENDED MARCH 31, 2025 | PAGE | | (1) Earnings Release | 2–11 | | Overview | 12 | | The Company | 12 | | Stock Information, Credit Ratings and Senior Unsecured Debt Covenants | 13 | | Financial Data | | | Selected Financial and Equity Information | 14 | | Net Operating Income (NOI) Comp ...

Financial Performance - Net revenues for the three months ended March 31, 2025, were $105,529 thousand, representing a 15.1% increase from $91,688 thousand in the same period of 2024[12] - Gross profit for the same period was $58,235 thousand, up from $47,780 thousand, indicating a gross margin improvement[12] - Net income increased to $8,790 thousand, compared to $3,954 thousand in the prior year, reflecting a 122.5% year-over-year growth[12] - Earnings per share (EPS) for the quarter were $0.15, compared to $0.07 in the same quarter of 2024, marking a 114.3% increase[12] - The Company reported a total comprehensive income of $9,630 thousand for the quarter, compared to $2,857 thousand in the prior year[15] - For the three months ended March 31, 2025, net revenues were $105,529,000, a 15% increase from $91,688,000 in the same period of 2024[83] - Net income for the three months ended March 31, 2025, was $8,790,000, compared to $3,954,000 for the same period in 2024, representing a 122% increase[83] - Basic earnings per share increased to $0.15 for the three months ended March 31, 2025, up from $0.07 in 2024[71] Cash Flow and Equity - Cash flows from operating activities were $26,386 thousand, significantly higher than $15,905 thousand in the prior year[20] - Total stockholders' equity at the end of the period was $735,815 thousand, slightly down from $738,178 thousand a year earlier[18] - The company ended the quarter with cash and cash equivalents of $49,614 thousand, down from $56,443 thousand at the end of the same quarter in 2024[20] Stock Repurchase and Dividends - The company repurchased common stock worth $23,098 thousand during the quarter, compared to $14,641 thousand in the same period of 2024[20] - The Company repurchased approximately 404,000 shares of common stock for $23.1 million during the three months ended March 31, 2025, leaving $25.0 million remaining under the repurchase authorization[65] - The Company declared dividends of $0.20 per share to be paid to stockholders of record at the end of each quarter in 2024[66] - The Company declared a quarterly cash dividend of $0.21 per share for the fourth quarter of 2024, an increase from the previous $0.20 per share[67] Research and Development - Research and development expenses increased to $24,095 thousand from $23,225 thousand, reflecting ongoing investment in innovation[12] - Research and development expenses for the three months ended March 31, 2025, were $21,845,000, up from $20,800,000 in 2024, reflecting a 5% increase[83] Customer Concentration - The Company's top ten customers accounted for approximately 80% of net revenues for the three months ended March 31, 2025, compared to 77% in 2024[56] - As of March 31, 2025, 86% of accounts receivable were concentrated with the Company's top ten customers, slightly down from 87% at December 31, 2024[59] - Sales to distributors were $75.2 million for the three months ended March 31, 2025, up from $66.4 million in 2024, representing a growth of 13.2%[56] Marketable Securities and Allowance for Credit Losses - Total marketable securities amounted to $239.682 million as of March 31, 2025, up from $249.023 million as of December 31, 2024, showing a decline of about 3.75%[40][42] - The allowance for credit losses decreased to $55,000 as of March 31, 2025, from $436,000 as of December 31, 2024, representing a reduction of approximately 87.39%[30] - The company maintains an allowance for estimated credit losses, which is adjusted based on the aging of accounts receivable and customer creditworthiness[29] Other Financial Metrics - Total stock-based compensation expense for the three months ended March 31, 2025, was approximately $8.7 million, an increase of 35.4% from $6.4 million in the same period of 2024[45][47] - The Company's effective tax rate for the three months ended March 31, 2025, was 11.1%, significantly higher than the 0.5% effective tax rate in 2024[73] - The Company reported other income of $3,167,000 for the three months ended March 31, 2025, compared to $3,502,000 in 2024[83] Acquisitions and Future Projections - The Company completed the acquisition of Odyssey Semiconductor Technologies for $9.52 million in cash on July 1, 2024, to enhance its GaN technology development[90] - The estimated future amortization expense for finite-lived intangible assets is projected to be $1.677 million for the fiscal year 2025[34] - The Company is currently evaluating the impact of ASU 2024-03 on its financial statement disclosures, which will require additional disclosures starting in 2026[27] - The Company expects the fair value of marketable securities to recover as they reach maturity, as issuers continue to make timely interest payments[44]

Revenue - Revenue for the first quarter of 2025 was $7.5 million, compared to nil for the same period in 2024, due to a milestone payment from the Neurocrine collaboration[18] - Revenue for Q1 2025 was $7.5 million, compared to $0 in Q1 2024[24] Expenses - Research and development expenses increased to $61.2 million in Q1 2025 from $44.3 million in Q1 2024, primarily due to ongoing Phase 3 clinical trials for azetukalner[18] - General and administrative expenses rose to $19.0 million in Q1 2025 from $14.8 million in Q1 2024, attributed to increased personnel-related costs[18] - Research and development expenses increased to $61.2 million in Q1 2025 from $44.25 million in Q1 2024, representing a 38.3% increase[24] - General and administrative expenses rose to $19.038 million in Q1 2025, up from $14.791 million in Q1 2024, a 28.5% increase[24] - Total operating expenses for Q1 2025 were $80.238 million, compared to $59.041 million in Q1 2024, reflecting a 36% increase[24] Net Loss - Net loss for Q1 2025 was $65.0 million, compared to $47.9 million in Q1 2024, driven by higher R&D expenses and lower interest income[18] - Loss from operations for Q1 2025 was $72.738 million, compared to a loss of $59.041 million in Q1 2024[24] - Net loss for Q1 2025 was $65.047 million, compared to a net loss of $47.931 million in Q1 2024, indicating a 36.0% increase in losses[24] - Basic and diluted net loss per common share for Q1 2025 was $0.83, compared to $0.62 in Q1 2024[24] - Comprehensive loss for Q1 2025 was $64.271 million, compared to $49.623 million in Q1 2024[24] Cash Position - Cash and cash equivalents and marketable securities totaled $691.1 million as of March 31, 2025, down from $754.4 million as of December 31, 2024[13] - The company expects to have sufficient cash to fund operations into 2027 based on current operating plans[13] Clinical Trials - Patient recruitment for the Phase 3 X-TOLE2 epilepsy study is expected to complete in the next few months, with topline results anticipated in early 2026[3] - The first Phase 3 MDD study, X-NOVA2, is currently enrolling patients, with the second study, X-NOVA3, expected to initiate mid-year 2025[14] - A Phase 1 study for the follow-on Kv7 candidate, XEN1120, has been initiated, with an IND filing for lead candidate XEN1701 anticipated in Q3 2025[4] - Azetukalner is the most advanced potassium channel modulator in late-stage clinical development for epilepsy and neuropsychiatric disorders[5] Share Information - Weighted average common shares outstanding increased to 78,687,503 in Q1 2025 from 77,594,599 in Q1 2024[24] Other Income - Other income decreased to $8.118 million in Q1 2025 from $11.522 million in Q1 2024[24]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-38599 Aquestive Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of Inco ...

P R E S S R E L E A S E RICHMOND, Va., May 12, 2025 – The Brink's Company (NYSE:BCO), a leading global provider of cash and valuables management, digital retail solutions (DRS), and ATM managed services (AMS), today announced first-quarter results. Mark Eubanks, president and CEO, said: "We delivered strong performance in the first quarter with EBITDA and EPS exceeding the top end of our guidance range. Organic revenue growth of 6% included 20% growth in AMS and DRS. On a trailing-twelve month basis, these ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT For the transition period from to Commission File Number (001-40140) , RIGETTI COMPUTING, INC. (Exact name of registrant as specified in its charter) Delaware 88-0950636 (State or other jurisdictio ...

REPAY Reports First Quarter 2025 Financial Results Company Provides 2025 Outlook Including Accelerating Growth Announced Conclusion of Strategic Review Process Announced Increased Share Repurchase Program Authorization to $75 million ATLANTA, May 12, 2025 -- Repay Holdings Corporation (NASDAQ: RPAY) ("REPAY" or the "Company"), a leading provider of vertically-integrated payment solutions, today reported financial results for its first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights | ( ...

Portfolio Overview - As of March 31, 2025, the portfolio totaled $1,213.6 million, with 41% in first lien secured debt and a weighted average yield on interest-bearing debt investments of 12.0%[234] - As of September 30, 2024, the portfolio totaled $1,328.1 million, with 50% in first lien secured debt and a weighted average yield on interest-bearing debt investments of 12.3%[235] - The average investment size in the overall portfolio was $6.9 million as of March 31, 2025[234] - PSLF's portfolio as of March 31, 2025, totaled $1,392.9 million, with a weighted average yield on interest-bearing debt investments of 10.4%[239] - As of March 31, 2025, the PennantPark Senior Loan Fund (PSLF) had total assets of $1,463.5 million, an increase from $1,073.4 million as of September 30, 2024[293] - The investment portfolio of PSLF consisted of debt investments in 119 portfolio companies as of March 31, 2025, compared to 102 companies as of September 30, 2024[293] Investment Activity - For the three months ended March 31, 2025, the company invested $176.8 million in three new and 52 existing portfolio companies, with a weighted average yield on debt investments of 10.7%[236] - For the three months ended March 31, 2024, the company invested $188.5 million in six new and 43 existing portfolio companies, with a weighted average yield of 11.7%[237] - For the six months ended March 31, 2025, PSLF invested $523.7 million in 23 new and 57 existing portfolio companies[240] - For the six months ended March 31, 2024, PSLF's total investments amounted to $194.2 million, with a weighted average yield of 12.2%[241] Financial Performance - For the three and six months ended March 31, 2025, investment income was $30.7 million and $64.9 million, respectively, a decrease from $36.0 million and $70.3 million for the same periods in 2024[270] - For the three and six months ended March 31, 2025, expenses totaled $19.2 million and $40.4 million, respectively, down from $21.7 million and $40.4 million in 2024[271] - Net investment income for the three and six months ended March 31, 2025, was $11.4 million and $24.4 million, or $0.18 and $0.37 per share, compared to $14.3 million and $29.9 million, or $0.22 and $0.46 per share in 2024[272] - For the three and six months ended March 31, 2025, net realized losses totaled $(27.7) million and $(30.3) million, compared to $(31.0) million and $(29.2) million in 2024[273] - The net change in unrealized appreciation on investments for the three and six months ended March 31, 2025, was $27.1 million and $29.5 million, respectively, down from $33.2 million and $28.3 million in 2024[274] Debt and Financing - The company expects to continue using debt capital and proceeds from public and private offerings to finance investment objectives[228] - The Truist Credit Facility had outstanding borrowings of $314.5 million as of March 31, 2025, with a weighted average interest rate of 6.7%[280] - PSLF entered into a $400.0 million senior secured revolving credit facility, increased from $325.0 million in August 2024[296] - The company has not engaged in interest rate hedging activities during the reporting periods, which may expose it to risks associated with interest rate fluctuations[326] Cash and Liquidity - As of March 31, 2025, the company had cash and cash equivalents of $32.6 million, down from $49.9 million as of September 30, 2024[289] - For the six months ended March 31, 2025, operating activities provided cash of $161.1 million, while financing activities used cash of $178.3 million, primarily for credit facility repayments and stockholder distributions[290] - Cash and cash equivalents increased to $62,201,000 as of March 31, 2025, from $36,595,000 as of September 30, 2024, reflecting a growth of 70%[309] Distributions - The company must distribute dividends equal to at least 90% of its net ordinary income and realized net short-term capital gains to maintain its RIC tax election[259] - The company declared distributions of $0.24 per share for the three months ended March 31, 2025, compared to $0.21 per share in the same period of 2024, reflecting a 14.3% increase[314] - The company transitioned from quarterly to monthly distributions effective October 2023, with future monthly distributions determined by the board of directors[315] Valuation and Accounting - PSLF's portfolio generally consists of illiquid securities, and the board of directors undertakes a multi-step valuation process each quarter for investments without readily available market quotations[246] - The company has adopted ASC 825-10 for the Truist Credit Facility, incurring $0.3 million in expenses related to amendment costs for the three and six months ended March 31, 2025[252] - The company has adopted ASU 2022-03, which clarifies fair value measurement disclosures, with no material impact on consolidated financial statements[320] - The FASB issued ASU 2023-07, effective for fiscal years beginning after December 15, 2023, which will enhance segment disclosure requirements, currently under evaluation by the company[321] Market and Sector Analysis - The average coupon rates for various sectors include 11.55% for software and 10.69% for transportation, indicating a diverse interest rate environment across industries[303] - The healthcare, education, and childcare sector shows a notable interest rate of 10.65% for NORA Acquisition, LLC, highlighting the sector's investment attractiveness[303] - The company has a diverse portfolio with investments across various sectors, including aerospace and defense, healthcare, and business services, indicating a strategic approach to market expansion[303]